Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Bonus plan approved
Inv. presentation
Acq. announced
Director departure
CUBIST PHARMACEUTICALS INC (CBST) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/21/2015 8-K Quarterly results
01/13/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Cubist Announces Withdrawal of Listing of CVRs from NASDAQ Global Select Market"
01/02/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Failure Purchase Notice"
12/22/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "ZERBAXA addresses certain serious and resistant Gram-negative bacteria First new antibiotic approved in U.S. under the GAIN Act that treats Gram-negative bacteria"
12/19/2014 8-K Temporary Suspension of Trading Under Registrant's Employee Benefit Plans, Financial Statements and Exhibits
Docs: "Notice pursuant to Rule 104(b)(2)(i) of Regulation BTR"
12/09/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Cubist Comments on CUBICIN Patent Litigation"
12/08/2014 8-K Bonus plan approved/adopted
Docs: "Agreement and Plan of Merger, among Merck & Co., Inc., Mavec Corporation and Cubist Pharmaceuticals, Inc. Schedules to the Agreement and Plan of Merger have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The registrant will furnish copies of any such schedules to the U.S. Securities and Exchange Commission upon request",
"Amended and Restated Bylaws of Cubist Pharmaceuticals, Inc. (marked)",
"Cubist Pharmaceuticals, Inc. 2014 Severance Plan and Summary Plan Description",
"Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash Acquisition Augments Merck's Strong Foundation and Opportunity for Growth in Hospital Acute Care Market"
11/06/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Cubist Names Dr. Patrick Vink Chief Operating Officer"
10/22/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Cubist Pharmaceuticals Names Robert J. Perez Chief Executive Officer"
10/21/2014 8-K Quarterly results
Docs: "shall be deemed to be furnished, and not filed:"
08/11/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Senior Director, Corporate Communications"
08/06/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Senior Director, Corporate Communications"
07/22/2014 8-K Quarterly results
Docs: "shall be deemed to be furnished, and not filed:"
07/14/2014 8-K Entry into a Material Definitive Agreement
06/23/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "SIVEXTRO offers a short six-day course of therapy to physicians in once daily I.V. and oral treatment options"
06/04/2014 8-K Submission of Matters to a Vote of Security Holders
06/02/2014 8-K Other Events
04/22/2014 8-K Quarterly results
Docs: "CUBIST PHARMACEUTICALS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS",
"Cubist Announces Submission of New Drug Application for Investigational Antibiotic Ceftolozane/tazobactam"
04/01/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CUBIST APPOINTS ROBERT J. PEREZ TO BOARD OF DIRECTORS"
02/28/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "CUBIST ANNOUNCES EMA ACCEPTANCE OF TEDIZOLID MARKETING AUTHORIZATION APPLICATION FOR REVIEW"
02/21/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/23/2014 8-K Quarterly results
Docs: "CUBIST REPORTS FOURTH QUARTER AND FULL YEAR 2013 FINANCIAL RESULTS; PROVIDES 2014 REVENUE GUIDANCE"
01/13/2014 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "CUBIST ANNOUNCES FOURTH QUARTER/FULL-YEAR 2013 REVENUES; PROVIDES PIPELINE UPDATE"
12/18/2013 8-K/A Financial Statements and Exhibits
Docs: "Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm"
12/16/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "CUBIST ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 TRIAL OF CEFTOLOZANE/TAZOBACTAM IN INTRA-ABDOMINAL INFECTIONS"
11/26/2013 8-K Other Events
11/25/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "CUBIST ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 TRIAL OF INVESTIGATIONAL ANTIBIOTIC CEFTOLOZANE/TAZOBACTAM IN COMPLICATED URINARY TRACT INFECTIONS"
11/22/2013 8-K/A Financial Statements and Exhibits
Docs: "Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm",
"Unaudited Pro Forma Condensed Combined Financial Statements"
10/24/2013 8-K Form 8-K - Current report
10/22/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "CUBIST ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR INVESTIGATIONAL ANTIBIOTIC TEDIZOLID FOR TREATMENT OF SERIOUS SKIN INFECTIONS"
10/22/2013 8-K Quarterly results
Docs: "CUBIST REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS"
09/10/2013 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Indenture, between Cubist Pharmaceuticals, Inc. and the Bank of New York Mellon Trust Company, N.A. (including the form of the 1.125% Convertible Senior Note due 2018)",
"Indenture, between Cubist Pharmaceuticals, Inc. and the Bank of New York Mellon Trust Company, N.A. (including the form of the 1.875% Convertible Senior Note due 2020)",
"Additional convertible bond hedge transaction confirmation, by and between Morgan Stanley & Co. International plc and Cubist Pharmaceuticals, Inc., in reference to the 1.125% Convertible Senior Notes due 2018",
"Additional convertible bond hedge transaction confirmation, by and between Barclays Bank PLC and Cubist Pharmaceuticals, Inc., in reference to the 1.125% Convertible Senior Notes due 2018",
"Additional convertible bond hedge transaction confirmation, by and between Royal Bank of Canada and Cubist Pharmaceuticals, Inc., in reference to the 1.125% Convertible Senior Notes due 2018",
"Additional issuer warrant transaction confirmation, by and between Morgan Stanley & Co. International plc and Cubist Pharmaceuticals, Inc., in reference to the 1.125% Convertible Senior Notes due 2018",
"Additional issuer warrant transaction confirmation, by and between Barclays Bank PLC and Cubist Pharmaceuticals, Inc., in reference to the 1.125% Convertible Senior Notes due 2018",
"Additional issuer warrant transaction confirmation, by and between Royal Bank of Canada and Cubist Pharmaceuticals, Inc., in reference to the 1.125% Convertible Senior Notes due 2018",
"Additional convertible bond hedge transaction confirmation, by and between Morgan Stanley & Co. International plc and Cubist Pharmaceuticals, Inc., in reference to the 1.875% Convertible Senior Notes due 2020",
"Additional convertible bond hedge transaction confirmation, by and between Barclays Bank PLC and Cubist Pharmaceuticals, Inc., in reference to the 1.875% Convertible Senior Notes due 2020"
09/03/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "CUBIST PHARMACEUTICALS ANNOUNCES PROPOSED OFFERING OF $600 MILLION OF CONVERTIBLE SENIOR NOTES"
08/29/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "FOR IMMEDIATE RELEASE - August 29, 2013, Lexington, Mass."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy